Lisocabtagene maraleucel Disease Interactions

Lisocabtagene maraleucel should not be administered to patients with active infection or inflammatory disorders. Monitor patients for signs or symptoms of infection and treat appropriately.

Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells, such as lisocabtagene maraleucel. Screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing is advised. In patients with prior history of HBV, consider concurrent antiviral suppressive therapy to prevent HBV reactivation per standard guidelines.